Skip navigation

Oxford Health NHS Foundation Trust

Skip to main content Skip to footer Accessibility help

Research & Development

There are many ways to get involved with research, at Oxford Health NHS Foundation Trust

Research trials

Take part in research now

We have several studies which are currently open for recruitment. For all of these studies, it is possible to take part remotely (e.g. participate online or over the phone). If you are interested in taking part, please contact mentalhealthresearch@oxfordhealth.nhs.uk.

Studies for everyone

Psychological Understanding of Pandemics (PUPs) is a questionnaire study which will help us understand how the current situation is affecting people’s wellbeing. The study is sponsored by Oxford Health NHS Foundation Trust and anyone living or working in Oxfordshire or Buckinghamshire who is over 18 years old can take part. To take part, or to find out more information about the study, please visit https://oxford.onlinesurveys.ac.uk/psychological-understanding-of-pandemics

CLIMB is an online survey aiming to establish patient and public views on the sharing of NHS and health data (both for clinical purposes and de- identified health data for research).  This includes looking at current understanding of health data sharing, how individuals would like to see their health data shared and with whom. The anonymous survey can be accessed via https://www.climbproject.org.uk/

The Arts Therapies study has been designed to collect information about what people know about arts therapies and which modality they would choose if they were seeking treatment. 

CAP-MEM aims to investigate if the autonomic nervous system works differently in people with mental health, neurodevelopmental and neurodegenerative disorders and the study also aims to evaluate whether the autonomic nervous system is affected by the severity of the disorder or by medication use. Participation involves completing a questionnaire and optional cognitive tasks. 

Studies for people with mental health difficulties

PREFER is a questionnaire study to establish patient preferences for voice-hearing therapies. There are lots of different types of psychological (talking) therapies for the experience of hearing distressing voices. However, there hasn’t been any research about patient preferences for these therapies. The PREFER study aims to find out more about patient preferences, including where you think therapy should take place, what you think therapy should involve and what you think therapy should focus on and try to help with. The study aims to help clinicians and researchers to develop and offer therapies that better match with the patients’ preferences.

NEON-O is an online trial aiming to explore the effect of using recovery stories to improve mental wellbeing and quality of life; with the aim to create an online support system like this in the future. Participants who experience difficulties with their mental health (apart from experiences of psychosis) are randomly allocated to either use an online programme with access to recovery stories immediately or will have to wait 1 year before they can access the online support. Participants have 4 follow-up sessions throughout a year; completing a small set of questionnaires each time.

ESCAPE assesses the benefits of integrating a smoking cessation treatment into routine Psychological care for depression and anxiety. People who currently smoke and are receiving support from IAPT Services will be invited to take part.

Studies for people with anxiety and/or depression

GLAD aims to explore the genetic predictors and environmental risk factors for depression and anxiety. Participants will be given the opportunity to donate a saliva sample to the NIHR Mental Health Biobank, which we hope will be a leading resource for future health and social care research. Anyone who has been diagnosed with or treated for anxiety or depression at one stage in their lifetime can participate in this study.

Studies for people with psychosis

Hearing Nasty Voices is a study which is looking to understand why people can find their auditory hallucinations difficult to ignore or dismiss. Participants who experience voices that are critical and/or derogatory will complete a set of questionnaires online or on paper and receive £5 on completion.

NEON is an online trial aiming to explore the effect of using recovery stories to improve mental wellbeing and quality of life for people experiencing psychosis. Participants are randomly allocated to either use an online programme with access to recovery stories immediately or will have to wait 1 year before they can access the online support. Participants have 4 follow-up sessions throughout the period of a year; completing a small set of questionnaires each time and will receive a £20 voucher via email each time a follow-up is completed.

Relationship status and wellbeing is a study investigating if and how satisfaction with a romantic relationship might increase wellbeing in those who hear voices or feel persecuted, also referred to as experiencing psychosis. Participation involves completing a set of questionnaires taking around 30-60 minutes.

PPIP2 is a pilot study that aims to test enough patients with psychosis to be able to define the prevalence of schizophrenia that is caused by an antibody mediated disorder. Participation involves a blood sample and permission to store the sample for future testing. Participants receive £10 reimbursement for their time.

Studies for carers of people with mental health problems

NEON-C is an online trial aiming to explore the effect of using recovery stories to support those who care for individuals with mental health conditions. Participants are randomly allocated to use an online programme with access to recovery stories immediately or will have to wait 1 year before they can access the online support. Participants have 4 follow-up sessions throughout the period of a year; completing a small set of questionnaires each time.

Studies for NHS staff

PROMISE is a research study for NHS Staff. The study is looking at predictors of engagement with mindfulness meditation. By taking part in the study, you will be provided with a year’s long subscription to Headspace, free of charge. bit.ly/PROMISESTUDY 

Register your interest in research

Many of our studies involve face to face appointments, which we may not be able to offer to new participants under the current circumstances. Register your interest with us at mentalhealthresearch@oxfordhealth.nhs.uk and we will contact you once our studies are running again.

Children and Young People

Assessing Mistrust in Young People aims to assess levels of mistrust in young people attending child and mental health services. Participation involves a 5-minute questionnaire.

Parent-Adolescent Interactions in the Treatment of Adolescents with Depression (PAI) is an interview study aiming to understand how adolescents respond to treatment and how to directly target depression more effectively. Participation involves an interview with a researcher.

Depression

LQD aims to compare the clinical and cost effectiveness of lithium versus quetiapine when used as add-on therapies to antidepressant medication for patients with Treatment Resistant Depression (TRD). Participation involves pre-screening questions usually delivered over the phone. Following this a full screening and baseline assessment will be completed (this involves completing study questionnaires and having blood samples and physical observations taken). Participants are then randomised to either lithium or quetiapine. A research assistant will then meet with the participant at 8, 26 and 52 weeks to complete further questionnaires and blood tests. Participants also complete weekly True Colours self-rated questionnaires.

TACK II invites patients and mental health professionals to assess the effectiveness of DIALOG+, an app developed for clinicians working with patients with depression. The study is a randomized controlled trial, where clinicians will either work with patients using the DIALOG+ app, or follow usual care. This new approach has already been found to improve the quality of life of people with psychosis and we are hoping that patients with depression may experience similar benefits.

Dementia

DLB Genetics Very little is known about the cause of Lewy Body Dementia (DLB), so by comparing the subtle differences in the genes of groups of people with and without DLB we can discover clues about which processes in our bodies may cause the condition. Researchers have found more than 20 genes that are associated with AD and this study aims to translate the expertise gained from the AD Genetics study to understand more about DLB. Participation involves a one-off visit to your home from a research nurse/practitioner which lasts around 2 hours and includes answering questions, providing a blood sample and a family member or friend also answering some questions.

IDEAL-2 This study will build on the unique resource of the established IDEAL national study which aims to identify key indicators of quality of life and living well with dementia. IDEAL-2 will continue to follow the original participants and their carers for three further years but it will also include additional participants, specifically people with young onset dementia and less common dementia subtypes.

ILiAD People with Alzheimer’s disease are more prone to seizures than people of the same age without dementia. It is also possible that patients with Alzheimer’s disease have abnormal electrical activity in their brains that may be stabilised with anti-epileptic medication. We are investigating whether Levetiracetam (an anti-epileptic medication) may also have an additional role in helping memory difficulties in patients with Alzheimer’s disease.  The study is of a cross-over design meaning that all participants will receive Levetiracetam. Half of patients will receive placebo first and half will receive Levetiracetam first. After twelve weeks, patients will be switched from placebo to Levetiracetam and vice versa.

PATHFINDER Problem Adaptation Therapy (PATH) is a new form of talking therapy for people with mild-moderate dementia and depression. PATH aims to help people with Alzheimer’s disease and their carers to find ways that they can change their environment and activities so that they can enjoy a more positive state of mood. PATHFINDER is a randomised-control trial evaluating the effectiveness of the PATH intervention using a newly adapted manual. Participants are randomly allocated to either 12 weeks of the modified PATH treatment or current treatment offered as usual within the NHS. Outcomes are measured at 0, 3, 6 and 12 months. The most important outcome is improvement in symptoms of depression at 6 months.

PrAISED This is a research study that will test the effectiveness of an activity and exercise programme for people with memory problems. In this study, we want to test two therapy packages with different levels of support.
– Therapy package 1 is standard falls prevention assessment and advice that is normally available from the NHS.
– Therapy package 2 involves support from occupational therapists, physiotherapists and rehabilitation support workers over one year. The number of visits received will depend on peoples’ needs and preferences.

EPAD  The European Prevention of Alzheimer’s Dementia Longitudinal Cohort study is a unique and ground-breaking European initiative to streamline the testing and development of preventative treatments for Alzheimer’s disease. It is the largest ever public-private partnership in Alzheimer’s disease research, combining knowledge and expertise from 39 organisations across multiple sectors. EPAD will develop a platform on which new compounds can be tested in a streamlined and efficient way, delivering more effective, targeted interventions that can slow or stop dementia.

NTAD New Therapeutics in Alzheimers Disease will employ magnetoencephalography (MEG) to identify reliable, sensitive and tractable ‘biomarkers’ – biological signs – of abnormal brain structure that scientists believe is occurring early in Alzheimer’s disease. The aim is to develop a fit-for-purpose set of these identifiers based around MEG that can be used in studies which test novel interventions aimed at halting the progression of Alzheimer’s disease. 

Eating Disorders

TRIANGLE aims to establish whether an online platform of digital resources is helpful for individuals with anorexia nervosa, and their family member. Participation involves using the internet resources and completing online questionnaires.

Oxford Cognitive Approaches to Psychosis studies

Thrive is a research study run by Oxford Cognitive Approaches to Psychosis (OCAP). The aim of the study is to assess the effectiveness of VR Cognitive Treatment for persecutory delusions. Participants will either received 4 sessions of cognitive treatment (Virtual Reality Confidence Building) or 4 sessions of relaxation (Virtual Reality Mental Relaxation).

GameChange is also run by Oxford Cognitive Approaches to Psychosis (OCAP). The study aims to test automated Virtual Reality Cognitive Therapy for patients with fears in everyday social situations.

Perinatal Studies

CAPRI-Voc invites mothers who have experienced serious mental illness with infants aged between 9-18 months to explore different brain patterns of babies whose mums have experienced mental illness. The aim is to examine how the brain of infants processes voices and to understand how different factors may affect a child’s responses to sounds and voices.

Psychosis and schizophrenia

Alkermes intends to investigate if olanzapine and samidorphan (ALK 3831) can allow patients to have the benefits of olanzapine without the associated weight gain and metabolic risks.

BI is a study assessing the effectiveness of a clinical trial medication. The medication has been developed to improve cognitive function in patients with Schizophrenia. Patients are invited to participate in a Computerized Cognitive Training program alongside taking the medication. 

NCMH stands for National Centre for Mental Health. The centre are building a large database containing information about participants’ mental health, physical health, lifestyle and also anonymized genetic information. The cohort is hoped to be a world-leading resource for mental health and social care research. Participants take part in a one-off interview and also donate a blood or saliva sample.

Molgen is a study investigating genetic and non-genetic factors which may increase the risk of developing an Adverse Drug Reaction. This study focuses on Clozapine, which is an anti-psychotic medication.  

The OxMIV study is using routinely recorded electronic health record data on individuals previously assessed by Early Intervention in Psychosis services to validate an assessment tool that could help improve the process of violence risk assessment. Details of the study and use of data can be found at www.psych.ox.ac.uk/team/daniel-whiting

RADAR is a randomised trial which aims to assess the benefits and risks of a flexible, supported strategy for antipsychotic dose reduction and discontinuation where possible, in people with schizophrenia and non-affective psychosis.

The Sleep & Psychotic Features Study investigates the relationship between sleep and mood in people who have been referred to NHS mental health services, to understand if sleep problems are present in these people.

SCENE looks to develop new ways of supporting patients to improve their social networks and wellbeing. Patients with psychosis are invited to take part in a randomized controlled trial evaluating the effectiveness of working with a Social Coach for 6 months. Participants are invited to three follow up appointments over an 18-month period to assess wellbeing.  

To find out more about any of these studies, please email: mentalhealthresearch@oxfordhealth.nhs.uk

Home News Sitemap Search Support and advice Getting help Raising a concern Terms and conditions Contact us Access keys
  • Prescribed app

This is a prescribed app. It should only be used alongside a face to face intervention provided by a mental health worker. Check with your local service to see if they subscribe to the app.